Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 268

1.

CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.

Ishikura N, Kawata H, Nishimoto A, Nakamura R, Tsunenari T, Watanabe M, Tachibana K, Shiraishi T, Yoshino H, Honma A, Emura T, Ohta M, Nakagawa T, Houjo T, Corey E, Vessella RL, Aoki Y, Sato H.

Int J Oncol. 2015 Apr;46(4):1560-72. doi: 10.3892/ijo.2015.2860. Epub 2015 Jan 30.

PMID:
25634071
[PubMed - in process]
2.

Reprogramming of prostate cancer cells--technical challenges.

Borges GT, Vêncio EF, Vêncio RZ, Vessella RL, Ware CB, Liu AY.

Curr Urol Rep. 2015 Jan;16(1):468. doi: 10.1007/s11934-014-0468-4.

PMID:
25404182
[PubMed - in process]
3.

Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis.

Mostaghel EA, Morgan A, Zhang X, Marck BT, Xia J, Hunter-Merrill R, Gulati R, Plymate S, Vessella RL, Corey E, Higano CS, Matsumoto AM, Montgomery RB, Nelson PS.

PLoS One. 2014 Oct 30;9(10):e111545. doi: 10.1371/journal.pone.0111545. eCollection 2014.

PMID:
25356728
[PubMed - in process]
Free PMC Article
4.

Efficacy studies of an antibody-drug conjugate PSMA-ADC in patient-derived prostate cancer xenografts.

DiPippo VA, Olson WC, Nguyen HM, Brown LG, Vessella RL, Corey E.

Prostate. 2015 Feb;75(3):303-13. doi: 10.1002/pros.22916. Epub 2014 Oct 18.

PMID:
25327986
[PubMed - in process]
5.

Characterization of single disseminated prostate cancer cells reveals tumor cell heterogeneity and identifies dormancy associated pathways.

Chéry L, Lam HM, Coleman I, Lakely B, Coleman R, Larson S, Aguirre-Ghiso JA, Xia J, Gulati R, Nelson PS, Montgomery B, Lange P, Snyder LA, Vessella RL, Morrissey C.

Oncotarget. 2014 Oct 30;5(20):9939-51.

PMID:
25301725
[PubMed - in process]
Free PMC Article
6.

Targeting GPR30 with G-1: a new therapeutic target for castration-resistant prostate cancer.

Lam HM, Ouyang B, Chen J, Ying J, Wang J, Wu CL, Jia L, Medvedovic M, Vessella RL, Ho SM.

Endocr Relat Cancer. 2014 Dec;21(6):903-14. doi: 10.1530/ERC-14-0402. Epub 2014 Oct 6.

PMID:
25287069
[PubMed - in process]
7.

Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer.

Pritchard CC, Morrissey C, Kumar A, Zhang X, Smith C, Coleman I, Salipante SJ, Milbank J, Yu M, Grady WM, Tait JF, Corey E, Vessella RL, Walsh T, Shendure J, Nelson PS.

Nat Commun. 2014 Sep 25;5:4988. doi: 10.1038/ncomms5988.

PMID:
25255306
[PubMed - in process]
Free PMC Article
8.

Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype.

Saar M, Zhao H, Nolley R, Young SR, Coleman I, Nelson PS, Vessella RL, Peehl DM.

Cancer Lett. 2014 Sep 1;351(2):272-80. doi: 10.1016/j.canlet.2014.06.014. Epub 2014 Jul 3.

PMID:
24998678
[PubMed - indexed for MEDLINE]
9.

The role of the microenvironment-dormant prostate disseminated tumor cells in the bone marrow.

Lam HM, Vessella RL, Morrissey C.

Drug Discov Today Technol. 2014 Mar;11:41-7. doi: 10.1016/j.ddtec.2014.02.002. Review.

PMID:
24847652
[PubMed - indexed for MEDLINE]
10.

Androgen receptor splice variants determine taxane sensitivity in prostate cancer.

Thadani-Mulero M, Portella L, Sun S, Sung M, Matov A, Vessella RL, Corey E, Nanus DM, Plymate SR, Giannakakou P.

Cancer Res. 2014 Apr 15;74(8):2270-82. doi: 10.1158/0008-5472.CAN-13-2876. Epub 2014 Feb 20.

PMID:
24556717
[PubMed - indexed for MEDLINE]
11.

Prostate cancer derived prostatic acid phosphatase promotes an osteoblastic response in the bone microenvironment.

Larson SR, Chin J, Zhang X, Brown LG, Coleman IM, Lakely B, Tenniswood M, Corey E, Nelson PS, Vessella RL, Morrissey C.

Clin Exp Metastasis. 2014 Feb;31(2):247-56. doi: 10.1007/s10585-013-9625-2. Epub 2013 Nov 17.

PMID:
24242705
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling.

Nguyen HM, Ruppender N, Zhang X, Brown LG, Gross TS, Morrissey C, Gulati R, Vessella RL, Schimmoller F, Aftab DT, Corey E.

PLoS One. 2013 Oct 25;8(10):e78881. doi: 10.1371/journal.pone.0078881. eCollection 2013.

PMID:
24205338
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer.

Nyquist MD, Li Y, Hwang TH, Manlove LS, Vessella RL, Silverstein KA, Voytas DF, Dehm SM.

Proc Natl Acad Sci U S A. 2013 Oct 22;110(43):17492-7. doi: 10.1073/pnas.1308587110. Epub 2013 Oct 7.

PMID:
24101480
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Tumor necrosis factor receptor associated factor-4: an adapter protein overexpressed in metastatic prostate cancer is regulated by microRNA-29a.

Ahmed F, Shiraishi T, Vessella RL, Kulkarni P.

Oncol Rep. 2013 Dec;30(6):2963-8. doi: 10.3892/or.2013.2789. Epub 2013 Oct 8.

PMID:
24100420
[PubMed - indexed for MEDLINE]
15.

Absolute quantification by droplet digital PCR versus analog real-time PCR.

Hindson CM, Chevillet JR, Briggs HA, Gallichotte EN, Ruf IK, Hindson BJ, Vessella RL, Tewari M.

Nat Methods. 2013 Oct;10(10):1003-5. doi: 10.1038/nmeth.2633. Epub 2013 Sep 1.

PMID:
23995387
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia.

Cheng HH, Mitchell PS, Kroh EM, Dowell AE, Chéry L, Siddiqui J, Nelson PS, Vessella RL, Knudsen BS, Chinnaiyan AM, Pienta KJ, Morrissey C, Tewari M.

PLoS One. 2013 Jul 30;8(7):e69239. doi: 10.1371/journal.pone.0069239. Print 2013.

PMID:
23935962
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Establishment and serial passage of cell cultures derived from LuCaP xenografts.

Young SR, Saar M, Santos J, Nguyen HM, Vessella RL, Peehl DM.

Prostate. 2013 Sep;73(12):1251-62. doi: 10.1002/pros.22610. Epub 2013 Jun 6.

PMID:
23740600
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Inhibition of CCL2 Signaling in Combination with Docetaxel Treatment Has Profound Inhibitory Effects on Prostate Cancer Growth in Bone.

Kirk PS, Koreckij T, Nguyen HM, Brown LG, Snyder LA, Vessella RL, Corey E.

Int J Mol Sci. 2013 May 21;14(5):10483-96. doi: 10.3390/ijms140510483.

PMID:
23698775
[PubMed - in process]
Free PMC Article
19.

5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models.

Masoodi KZ, Ramos Garcia R, Pascal LE, Wang Y, Ma HM, O'Malley K, Eisermann K, Shevrin DH, Nguyen HM, Vessella RL, Nelson JB, Parikh RA, Wang Z.

Endocrinology. 2013 Jul;154(7):2296-307. doi: 10.1210/en.2012-2077. Epub 2013 May 13.

PMID:
23671262
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Dormancy in solid tumors: implications for prostate cancer.

Ruppender NS, Morrissey C, Lange PH, Vessella RL.

Cancer Metastasis Rev. 2013 Dec;32(3-4):501-9. doi: 10.1007/s10555-013-9422-z. Review.

PMID:
23612741
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk